A glucosamine chondroitin composition and preparation method thereof

Abstract

The present invention discloses a glucosamine chondroitin composition and a preparation method thereof, belonging to the field of health care products. The composition comprises a turmeric extract, a drynaria extract, an eucommia extract, a rehmannia extract, vitamin K, bovine collagen peptides, chondroitin sulfate, glucosamine hydrochloride, and lactic acid calcium. The present invention achieves an excellent bone density-enhancing effect by compounding the turmeric extract, the drynaria extract, the eucommia extract, the rehmannia extract, vitamin K, bovine collagen peptides, chondroitin sulfate, glucosamine hydrochloride, and lactic acid calcium.

Description

Technical Field

[0001] The present invention relates to the field of health care products, and in particular to a glucosamine chondroitin composition and a preparation method thereof. Background Art

[0002] Bone density is a key indicator of bone health. Decreased bone density can have profound consequences for individual health. For example, it can not only lead to osteoporosis and increase the risk of fractures, but can also cause a variety of complications, severely impacting patients' quality of life. Fractures are one of the most serious consequences of osteoporosis, particularly hip fractures, which carry extremely high rates of disability and mortality. Furthermore, decreased bone density can lead to cosmetic changes such as decreased height and hunchback, placing a psychological burden on patients.

[0003] Calcium is a key nutrient for maintaining bone density, accounting for approximately 99% of the body's total calcium. Calcium loss accelerates with aging, hormonal changes, and unhealthy lifestyle factors, leading to a gradual decrease in bone density. Therefore, calcium supplementation has become an important means of preventing and treating bone density loss.

[0004] Glucosamine chondroitin calcium tablets are a common health supplement used to prevent and treat bone and joint diseases. However, current glucosamine chondroitin calcium tablets on the market often have some issues, such as a short duration of efficacy and the need for frequent dosing. Long-term, high-dose use can cause side effects such as gastrointestinal discomfort, headaches, and dizziness. Therefore, how to enhance the calcium supplementation effect of glucosamine chondroitin calcium tablets by adding other ingredients has become a current research hotspot. Summary of the Invention

[0005] The present invention aims to provide a glucosamine chondroitin composition and a preparation method thereof. The glucosamine chondroitin composition is prepared using turmeric extract, drynaria extract, eucommia extract, rehmannia extract, vitamin K, bovine collagen peptide, chondroitin sulfate, glucosamine hydrochloride, and lactic calcium as raw materials, and has excellent effects of enhancing calcium absorption and increasing bone density.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a glucosamine chondroitin composition, comprising the following raw materials in parts by weight:

[0008] Turmeric extract: 2-4 parts;

[0009] Drynaria fortunei extract: 5-8 parts;

[0010] Eucommia ulmoides extract: 4-7 parts;

[0011] Rehmannia root extract: 3-5 parts;

[0012] Vitamin K: 2-6 servings;

[0013] Bovine collagen peptide: 5-10 parts;

[0014] Chondroitin sulfate: 2-4 parts;

[0015] Glucosamine hydrochloride: 3-6 parts;

[0016] Milk calcium: 20-30 parts;

[0017] The vitamin K consists of vitamin K1 and vitamin K2, wherein the mass ratio of vitamin K1 to vitamin K2 is 1:0.5-1.5.

[0018] Preferably, the glucosamine chondroitin composition comprises the following raw materials in parts by mass:

[0019] Turmeric extract: 3 parts;

[0020] Drynaria fortunei extract: 6 parts;

[0021] Eucommia ulmoides extract: 6 parts;

[0022] Rehmannia root extract: 4 parts;

[0023] Vitamin K: 4 parts;

[0024] Bovine collagen peptide: 7 parts;

[0025] Chondroitin sulfate: 3 parts;

[0026] Glucosamine hydrochloride: 5 parts;

[0027] Milk calcium: 25 parts;

[0028] The vitamin K consists of vitamin K1 and vitamin K2, wherein the mass ratio of vitamin K1 to vitamin K2 is 1:1.

[0029] In a second aspect, the present invention provides a calcium tablet having the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, the calcium tablet comprising the following components in parts by weight:

[0030] 50-60 parts of the glucosamine chondroitin composition of the first aspect;

[0031] Magnesium oxide: 5-10 parts;

[0032] Magnesium stearate: 0.5-2 parts;

[0033] Xylitol: 5-15 parts;

[0034] Sorbitol: 2-5 parts;

[0035] Vitamin D3: 0.1-0.3 parts;

[0036] 3wt% povidone K30 solution: 5-6 parts;

[0037] The 3 wt % povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol.

[0038] In a third aspect, the present invention provides a method for preparing the calcium tablet according to the second aspect, the method comprising the following steps:

[0039] S1. Magnesium oxide, xylitol, sorbitol, and vitamin D3 are sieved through an 80-mesh sieve and then mixed to obtain a mixture. Povidone K30 solution is added to the mixture to prepare wet granules, and the mixture is shaken and granulated using a 16-mesh sieve;

[0040] S2. Dry the granules prepared in S1 at 38°C for 0.5-1h and then sieve through a 20-mesh screen;

[0041] S3. Evenly mix the granules obtained in S2 with magnesium stearate using the equal-increment method, compress the mixture using a tablet press to obtain finished calcium tablets, and bottle the mixture.

[0042] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention provides a glucosamine chondroitin composition, which is composed of turmeric extract, drynaria extract, eucommia extract, rehmannia extract, vitamin K, bovine collagen peptide, chondroitin sulfate, glucosamine hydrochloride, and milk calcium. The turmeric extract and the rehmannia extract have anti-inflammatory and antioxidant effects, and can reduce bone loss by inhibiting inflammatory response and regulating osteoclast activity; drynaria extract and eucommia extract have the effects of tonifying the kidney and strengthening bones, promoting blood circulation and removing blood stasis, and can promote the generation and repair of bone cells; bovine collagen provides a rich collagen matrix for bones, which can promote calcium deposition and bone tissue repair; vitamin K can promote osteocalcin synthesis and fix calcium ions in the bone matrix; glucosamine hydrochloride and chondroitin sulfate can repair articular cartilage and reduce joint wear; and milk calcium can directly supplement calcium. The above raw materials synergize through multiple pathways to directly supplement calcium and promote absorption and deposition on the one hand, and regulate bone metabolism, repair bone tissue, enhance bone toughness, and comprehensively improve bone density and bone health on the other hand. DETAILED DESCRIPTION

[0043] In order to better understand the present invention, the present invention is further described below in conjunction with specific application examples, wherein the terms used in the application examples are for describing specific embodiments and do not constitute a limitation on the scope of protection of the present invention.

[0044] In the following examples, the experimental methods without specific conditions are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, the percentages and parts by mass are calculated.

[0045] Some of the raw materials and their sources are as follows:

[0046] Turmeric extract: purchased from Shanxi Lanyuan Biotechnology Co., Ltd., product number: lysw-0825-366;

[0047] Drynaria fortunei extract: purchased from Shanxi Hongchuang Biotechnology Co., Ltd., product number: SXHC-0706-111;

[0048] Eucommia ulmoides extract: purchased from Shaanxi New Horizon Biotechnology Co., Ltd., product number: XTYDZ01;

[0049] Rehmannia root extract: purchased from Shaanxi Xinyanghe Biotechnology Co., Ltd., product number: XYH-SDH-001;

[0050] Vitamin K1: purchased from Anhui Weimao Biotechnology Co., Ltd.

[0051] Vitamin K2: purchased from Jiangsu Baiyao Biotechnology Co., Ltd.

[0052] Bovine collagen peptide: purchased from Shanxi Shangnuoda Biotechnology Co., Ltd., product number SND-NGJYDBT;

[0053] Chondroitin sulfate: purchased from Blue Power Biotechnology (Xi'an) Co., Ltd., catalog number LL-202212101;

[0054] Glucosamine hydrochloride: purchased from Guangzhou Huiding Food Co., Ltd.

[0055] Milk calcium: purchased from Guangzhou Quanfeng Food Technology Co., Ltd.

[0056] Other raw materials were purchased commercially.

[0057] The raw materials and their mass proportions of the glucosamine chondroitin composition are shown in Table 1.

[0058] Table 1 Raw materials and mass ratios of glucosamine chondroitin composition

[0059]

[0060] Efficacy assay

[0061] Test 1: Bone density test

[0062] Test samples: Composition 1, compositions ①-⑥, each composition was prepared into a 100 mg / mL mixed solution using deionized water, and the feeding amount was as described in Table 2.

[0063] Experimental animals: OVX (bilateral ovariectomy) model SD rats weighing 250±5 g (purchased from Jintai Medi Biotechnology Co., Ltd.) were divided into 7 experimental groups and 1 control group, with 9 rats in each group.

[0064] The feed used for the experimental animals was AIN-93M standard feed, purchased from Xiaoshu Youtai (Beijing) Biotechnology Co., Ltd.

[0065] Trial period: 12 weeks.

[0066] Experimental method: During the experimental period, the experimental group was gavaged with the test sample daily, and the control group was gavaged with an equal amount of deionized water. Within 1 hour after the end of the experimental period, the rats were anesthetized by injection of 3.5w / v% chloral hydrate (10μL / g). The right femoral bone density of the rats was measured using dual-energy X-ray absorptiometry. The results are expressed as mean ± standard deviation.

[0067] Table 2 Bone density efficacy determination

[0068] experimental group Test samples Feeding amount <![CDATA[Mean bone mineral density of mice (g / cm 3 )]]> control group Deionized water 0.008mL / g·d 0.196±0.04 Experimental group 1 Composition 1 0.008mL / g·d <![CDATA[0.357±0.05 * ]]> Experimental group ① Composition ① 0.008mL / g·d <![CDATA[0.274±0.03 * ]]> Experimental group ② Composition ② 0.008mL / g·d <![CDATA[0.251±0.06 * ]]> Experimental group ③ Composition ③ 0.008mL / g·d <![CDATA[0.223±0.04 * ]]> Experimental group ④ Composition ④ 0.008mL / g·d <![CDATA[0.316±0.06 * ]]> Experimental group ⑤ Composition ⑤ 0.008mL / g·d <![CDATA[0.295±0.03 * ]]> Experimental group ⑥ Composition ⑥ 0.008mL / g·d <![CDATA[0.302±0.07 * ]]>

[0069] Note: “*” indicates significant difference compared with the control group, p < 0.05.

[0070] According to the comparison between composition 1 and compositions ①-⑥ in Table 1, the glucosamine chondroitin composition of the present invention has the effect of increasing bone density.

[0071] Comparing the results of composition 1 with compositions ①-③, it can be seen that the turmeric extract, rehmannia extract and vitamin K in the glucosamine chondroitin composition of the present invention can effectively synergize with other raw materials to enhance the effect of bone density.

[0072] Comparing the results of composition 1 with compositions ④-⑤, it can be seen that the mass ratio of vitamin K1 to vitamin K2 in the glucosamine chondroitin composition of the present invention has a certain effect on the improvement of bone density.

[0073] Comparing the results of composition 1 and composition ⑥, it can be seen that the dosage ratio of the various raw materials in the present invention has a certain effect on the improvement of bone density. Within the mass ratio range of the present invention, glucosamine chondroitin has a better effect on improving bone density.

[0074] Test 2: Acute toxicity test

[0075] Test substance: Composition 1-3; Composition 1-3 was prepared into a 1 g / mL mixed solution using deionized water.

[0076] Acute toxicity test: 60 SD rats weighing 250±5g, half male and half female, were selected; environment: temperature 23±1℃, humidity 54±2%.

[0077] The mixed solution of Compositions 1-3 samples was orally administered to rats once at the dosage shown in Table 3. The rats were fasted for 16 hours before gavage and observed for two consecutive weeks after gavage. The symptoms of poisoning and mortality were recorded as shown in Table 3. During the gavage period, the rats were fed with AIN-93M standard feed as normal.

[0078] Table 3 Acute toxicity test in mice

[0079] Group gender way dose Number of deaths Composition 1 male Oral 0.008mL / g·d 0 Composition 1 female Oral 0.008mL / g·d 0 Composition 2 male Oral 0.008mL / g·d 0 Composition 2 female Oral 0.008mL / g·d 0 Composition 3 male Oral 0.008mL / g·d 0 Composition 3 female Oral 0.008mL / g·d 0

[0080] The results of the acute toxicity test showed that the rats did not show obvious signs of poisoning and no animals died during the test, indicating that the composition prepared by the present invention is non-toxic.

[0081] Test 3: Stability and sensory evaluation test of calcium tablets with the effects of preventing calcium loss, promoting calcium absorption, and protecting joints

[0082] Accelerated shelf life testing was conducted for use cases 1-3. The calcium tablets were packaged in sealed polyethylene bottles. The accelerated conditions were a temperature of 40°C and a relative humidity of 75%. The accelerated duration was 8 weeks, with samples collected for testing at weeks 0, 2, 4, 6, and 8. Test indicators included the color, odor, and texture of the calcium tablets during the accelerated period. These indicators were evaluated as follows: At different accelerated time points, 20 sensory panelists evaluated the samples blindly (three groups of samples were randomly labeled A, B, and C). The evaluation method involved placing an equal number of samples on a porcelain plate as the sensory panelists evaluated the tablets. The samples were observed under natural light for color and texture, smelled, rinsed with warm water, and tasted.

[0083] Experimental Results: At week 0, the calcium tablets of Application Examples 1-3 exhibited uniform color; possessed a unique flavor and odor, with no foreign odor; and were dry, uniform tablets with no visible impurities. After eight weeks of accelerated testing, the calcium tablets of Application Examples 1-3 showed no visible differences compared to those at week 0, demonstrating stable properties.

[0084] Application Example 1:

[0085] A calcium tablet having the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, comprising the following components in parts by weight:

[0086] Glucosamine chondroitin composition (composition 1): 55 parts;

[0087] Magnesium oxide: 7 parts;

[0088] Magnesium stearate: 1.3 parts;

[0089] Xylitol: 10 parts;

[0090] Sorbitol: 4 parts;

[0091] Vitamin D3: 0.2 parts;

[0092] 3wt% povidone K30 solution: 5.5 parts;

[0093] The 3 wt% povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol;

[0094] The preparation method of the calcium tablet comprises the following steps:

[0095] S1. Magnesium oxide, xylitol, sorbitol, and vitamin D3 are sieved through an 80-mesh sieve and then mixed to obtain a mixture. Povidone K30 solution is added to the mixture to prepare wet granules, and the mixture is shaken and granulated using a 16-mesh sieve;

[0096] S2. Dry the granules prepared in S1 at 38°C for 0.75 h and then sieve them through a 20-mesh screen;

[0097] S3. Evenly mix the granules obtained in S2 with magnesium stearate using the equal-increment method, compress the mixture using a tablet press to obtain finished calcium tablets, and bottle the mixture.

[0098] Application Example 2: A calcium tablet having the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, the calcium tablet comprising the following components in parts by weight:

[0099] Glucosamine chondroitin composition (composition 1): 50 parts;

[0100] Magnesium oxide: 10 parts;

[0101] Magnesium stearate: 0.5 parts;

[0102] Xylitol: 15 parts;

[0103] Sorbitol: 2 parts;

[0104] Vitamin D3: 0.3 parts;

[0105] 3wt% povidone K30 solution: 5 parts;

[0106] The 3 wt% povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol;

[0107] The preparation method of the calcium tablet comprises the following steps:

[0108] S1. Magnesium oxide, xylitol, sorbitol, and vitamin D3 are sieved through an 80-mesh sieve and then mixed to obtain a mixture. Povidone K30 solution is added to the mixture to prepare wet granules, and the mixture is shaken and granulated using a 16-mesh sieve;

[0109] S2. Dry the granules prepared in S1 at 38°C for 0.5 h and then sieve them through a 20-mesh sieve;

[0110] S3. Evenly mix the granules obtained in S2 with magnesium stearate using the equal-increment method, compress the mixture using a tablet press to obtain finished calcium tablets, and bottle the mixture.

[0111] Application Example 3: A calcium tablet having the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, comprising the following components in parts by weight:

[0112] Glucosamine chondroitin composition (composition 1): 60 parts;

[0113] Magnesium oxide: 5 parts;

[0114] Magnesium stearate: 2 parts;

[0115] Xylitol: 5 parts;

[0116] Sorbitol: 5 parts;

[0117] Vitamin D3: 0.1 parts;

[0118] 3wt% povidone K30 solution: 6 parts;

[0119] The 3 wt% povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol;

[0120] The preparation method of the calcium tablet comprises the following steps:

[0121] S1. Magnesium oxide, xylitol, sorbitol, and vitamin D3 are sieved through an 80-mesh sieve and then mixed to obtain a mixture. Povidone K30 solution is added to the mixture to prepare wet granules, and the mixture is shaken and granulated using a 16-mesh sieve;

[0122] S2. Dry the granules prepared in S1 at 38°C for 1 h and then sieve them through a 20-mesh screen;

[0123] S3. Evenly mix the granules obtained in S2 with magnesium stearate using the equal-increment method, compress the mixture using a tablet press to obtain finished calcium tablets, and bottle the mixture.

[0124] The embodiments described above are some embodiments of the present invention, rather than all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but merely represents selected embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.

Claims

1. A glucosamine chondroitin composition, characterized in that It is composed of the following raw materials in parts by weight: Turmeric extract: 3 parts; Drynaria fortunei extract: 6 parts; Eucommia ulmoides extract: 6 parts; Rehmannia root extract: 4 parts; Vitamin K: 4 servings Bovine collagen peptide: 7 parts; Chondroitin sulfate: 3 parts; Glucosamine hydrochloride: 5 parts; Milk calcium: 25 parts; The vitamin K consists of vitamin K1 and vitamin K2, wherein the mass ratio of vitamin K1 to vitamin K2 is 1:

1.

2. A use of the glucosamine chondroitin composition according to claim 1 in the preparation of a health product, wherein the health product has the effect of increasing bone density.

3. The application according to claim 2, characterized in that: The dosage form of the health care product is any one of tablets, capsules and powders.

4. A calcium tablet, characterized in that: A composition comprising the glucosamine chondroitin composition according to claim 1.

5. The calcium tablet according to claim 4, characterized in that: Contains the following components by mass: The glucosamine chondroitin composition of claim 1: 50-60 parts; Magnesium oxide: 5-10 parts; Magnesium stearate: 0.5-2 parts; Xylitol: 5-15 parts; Sorbitol: 2-5 parts; Vitamin D3: 0.1-0.3 parts; 3wt% povidone K30 solution: 5-6 parts; The 3 wt % povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol.

Images